稳定报道时间 2026-10-02 12:00
SCOPE-AD：用于AD诊断的顺序成本感知序数信念规划
研究人员开发了SCOPE-AD，这是一种新的诊断阿尔茨海默病的方法，考虑了顺序证据获取的成本和患者负担。
01
证据
- AarXiv cs.AI一手来源2026-10-02 12:00
On ADNI, SCOPE-AD achieves 77.70\% Macro-F1 at an average acquisition cost of \$50.46, exceeding the strongest evaluated baseline by 9.34 percentage points.
- AarXiv cs.AI一手来源2026-10-02 12:00
On ADNI, SCOPE-AD achieves 77.70\% Macro-F1 at an average acquisition cost of \$50.46
- AarXiv cs.AI一手来源2026-10-02 12:00
Abstract: Alzheimer's disease (AD) diagnosis requires sequential evidence acquisition under heterogeneous test costs and patient burden. Fixed-modality predictors do not jointly decide which test to acquire or when the available evidence is sufficient for diagnosis. We propose SCOPE-AD (Sequential Cost-Aware Ordinal-Belief Planning with Energy-Based Models for Diagnostic Agents) for cost-aware cl…